Sarepta Therapeutics (NASDAQ:SRPT) is up 8% premarket on higher-than-normal volume in response to an upgrade by BofA to Buy with a price target of $21. The analyst ups the probability of FDA clearance of eteplirsen to 50% from 40%, bringing it up to at least a coin toss's chance of approval.